Kamada Projects Strong Double-Digit Revenue and EBITDA Growth for 2026
KMDA sits 40% above its 52-week low of $5.54.
Summary
Kamada Ltd. announced optimistic 2026 financial guidance, projecting double-digit revenue and adjusted EBITDA growth driven by organic expansion, while also affirming its 2025 targets.
Key Events · Earnings and Guidance · KMDA
-
2026 Financial Guidance
Kamada forecasts 2026 revenues between $200 million and $205 million, and adjusted EBITDA between $50 million and $53 million.
-
Double-Digit Organic Growth
The 2026 guidance represents a year-over-year increase of 13% in revenues and 23% in adjusted EBITDA (mid-point basis), based solely on continued organic growth.
-
2025 Guidance Affirmed
The company reaffirmed its 2025 financial guidance of $178 million - $182 million in revenues and $40 million - $44 million of adjusted EBITDA, with approximately $75 million in year-end cash.
-
Strategic Expansion
Growth is expected from expanding the commercial product portfolio, launching biosimilars, extending distribution to the MENA region, and increasing plasma collection.
Analysis · KMDA · Life Sciences
Kamada Ltd. has provided robust financial guidance for 2026, forecasting significant double-digit increases in both revenues and adjusted EBITDA, driven by organic growth. This positive outlook, coupled with the affirmation of its 2025 financial targets and a healthy cash position, signals strong operational performance and strategic execution. The company's ability to project continued growth despite a reduction in GLASSIA royalty payments highlights the strength and diversification of its commercial product portfolio and plasma collection operations. Investors should view this guidance as a strong indicator of future profitability and market expansion.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 35.6% of the 1216 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KMDA was trading at $7.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $428.6M. The 52-week trading range was $5.54 to $9.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.